log in
All Press Releases | Back

Press Releases

Delphi 

April, 2018 - Stockholm, Sweden

 

 

Delphi advisor in connection with rights issue and listing of Fluicell AB (Publ) on Nasdaq First North

 

Delphi has acted as legal advisor to Fluicell AB (publ) in connection to a rights issue of 32,7 MSEK and listing on Nasdaq First North. The first day of trade is April 18.

Fluicell is based in Gothenburg Sweden and the company has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell's existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled. More information about the company is found on http://fluicell.com.

The Delphi team mainly consisted of Andreas Wirén (Partner), Daniel Jessen Winbo (Senior Associate) and Anders Hulegårdh (Partner).

Contact:
Andreas Wirén
Partner/Advokat
Delphi
Ph. +46 709 25 25 47
email: [email protected]


 

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | DISCLAIMER |  © World Services Group, 2018